Disarm Therapeutics

18 articles about Disarm Therapeutics

• 

  Lightstone Increases High-Impact Technologies Portfolio with $375M in New Fun...

  9/14/2021

  ​Lightstone Ventures recently announced the closing of Lightstone Ventures III, securing $375 million to invest in early-stage firms that develop high-impact technologies that can change lives. 

• Lilly Announces Agreement to Acquire Disarm Therapeutics

  10/15/2020

  Acquisition expands Lilly's R&D efforts in pain and neurodegeneration with the addition of Disarm's promising preclinical SARM1 programs for axonal degeneration   [15-October-2020]   INDIANAPOLIS and CAMBRIDGE, Mass. , Oct. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a definitive agreement to acquire Disarm Therapeutics, a privately-he

• 

  Eli Lilly Acquires Disarm Therapeutics in an Effort to Solve Axonal Degeneration

  10/15/2020

  Eli Lilly is betting on a new approach to axonal degeneration, announcing a definitive agreement to acquire Disarm Therapeutics, a privately-held biotech company committed to solving this mystery.
• 

  BioSpace Movers & Shakers, Jan. 17

  1/17/2020

  Pharma companies add new members to executive ranks and boards of directors.

• Disarm Therapeutics Appoints Veteran Biotech Executive Scott Holmes as Chief Financial Officer

  1/13/2020

  Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, today announced the appointment of Scott Holmes, M.S./MBA, as Chief Financial Officer

• Disarm Therapeutics Reports Preclinical Data Demonstrating Small Molecule SARM1 Inhibitors Preserve Both Axonal Structure and Function In Vitro and In Vivo

  10/22/2019

  Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, today announced preclinical data demonstrating that small molecule inhibitors of SARM1 protect axons in both in vitro and in vivo models of axonal degeneration.

• Disarm Therapeutics Presents Data at ECTRIMS 2019 Supporting SARM1 as a Novel Therapeutic Target for Multiple Sclerosis

  9/11/2019

  Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological disease, today announced preclinical data demonstrating that deleting SARM1 has a robust axonal-protective effect in experimental autoimmune encephalomyelitis (EAE), a well-accepted animal model of multiple sclerosis.

• Disarm Therapeutics Announces First Subject Enrolled in EPIPHANY Natural History Study of Chemotherapy-Induced Peripheral Neuropathy (CIPN)

  9/4/2019

  Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological disease, today announced the first subject enrolled in the ChemothErapy-Induced PerIPHeral NeuropAthy Natural HistorY Study (EPIPHANY).

• Disarm Therapeutics Announces Science Publications Elucidating Structure and Function of SARM1

  8/23/2019

  Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, today announced the publication of two articles in Science that significantly advance the understanding of the structure and function of SARM1, a protein that is a critical regulator of cellular degeneration, and provide further support for the centrality of the NAD+-cleavage pathway in mediating cellular degeneration across multiple species.

• Disarm Therapeutics Announces Appointment of Dr. Alvin Shih as President and Chief Executive Officer

  7/22/2019

  Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological disease, today announced the appointment of Alvin Shih, M.D., MBA, as President and Chief Executive Officer.

• Disarm Therapeutics Presents New Data Validating Role of SARM1 in Axonal Degeneration

  11/3/2018

  Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological disease, today announced data demonstrating that genetic inhibition of SARM1 prevents axonal degeneration in the central, ocular and peripheral nervous systems.

• Disarm Therapeutics Appoints Industry Leaders Robert Copeland, PhD, and Kimi Iguchi, CPA, to Board of Directors

  10/25/2018

  Disarm Therapeutics today announced that Robert Copeland, PhD, and Kimi Iguchi, CPA, have joined its board of directors.

• Disarm Therapeutics Presents Data Demonstrating the Protective Effect of SARM1 Deletion on Axonal Degeneration

  7/23/2018

  SARM1 deletion protects axons and prevents increases in neurofilament light chain (NF-L), a biomarker of axonal degeneration

• Disarm Therapeutics Expands Scientific Advisory Board with Experts in Neurology, Neuropathy, and Axonal Degeneration

  3/6/2018

  Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological disease, today announced new Scientific Advisory Board (SAB) members.

• Disarm Therapeutics Appoints Thomas Engber as Senior VP, Head of Neuropharmacology and Translational Sciences

  1/23/2018

  Dr. Engber's work in neuroscience spans three decades and includes research and leadership positions at the NIH, Cephalon, Pfizer, Biogen and most recently Takeda, where he was responsible for evaluating new technologies and advancing the company's CNS portfolio through partnerships.

• Disarm Therapeutics Appoints Peter Keller CBO

  12/19/2017

  Disarm Therapeutics today announced that Peter Keller is joining the company as Chief Business Officer on January 1, 2018.

• BioPharm Executive: Money Talk

  9/27/2017

  Venture capital is hopping, attracted to some of the past several years' successes.

• Biotech Startup Bonanza Continues as Disarm Therapeutics Emerges With $30 Million

  9/20/2017